Podcast
Medical News Podcast
Hosted by PeerDirect · EN
The Medical News Podcast by PeerDirect delivers news and interviews with clinical thought leaders and researchers to keep you informed of the latest breakthroughs, guidelines, and insights in your specialty. Designed for clinicians with stories selected by the PeerDirect editorial board. Visit us at peerdirect.com to sign-up for our newsletter.
87episodes
Episodes
Newest firstAll episodes
Could a new oral pan-RAS inhibitor finally change the outlook for KRAS-mutated pancreatic cancer?
May 1900:05:20Tap to summarizeThis episode of the PeerDirect Medical News Podcast explores promising new data on the oral pan-RAS inhibitor daraxonrasib in KRAS-mutated pancreatic cancer, a randomized stroke trial evaluating adjunctive tirofiban after tenecteplase, and AI-driven breast cancer risk prediction models that may outperform breast density alone. Together, these studies highlight emerging advances in targeted oncology, acute stroke management, and precision screening technologies that could influence future clinical practice.
Transcribe →ATTR-CM in 2026: Stabilizers vs Silencers – How Are You Choosing?
May 1800:12:15Tap to summarizeDrs. Sarswat and Dasgupta discuss contemporary decision-making in treating transthyretin amyloidosis, comparing oral stabilizers with subcutaneous silencers and emphasizing earlier diagnosis, phenotype-driven therapy, and individual patient preferences. They highlight how neuropathy and autonomic dysfunction influence choice of mechanism, review practical considerations such as side-effect profiles, dosing logistics, and drug–drug interactions, and briefly touch on emerging approaches like amyloid-removing and gene-targeted therapies.
Transcribe →Highlights From ISC 2026: The CREST-2 Cognitive Substudy and Oral Health and Stroke Risk
May 500:09:04Tap to summarizeDrs. Sanossian and Saver highlight emerging evidence that routine dental care and oral hygiene may function as actionable, modifiable contributors to stroke prevention beyond traditional vascular risk factors. They also review CREST-2 data showing that carotid revascularization in asymptomatic high-grade carotid stenosis reduces stroke risk, but does not appear to confer additional cognitive benefit over intensive medical therapy alone.
Transcribe →AI, Machine Learning, and HRCT in ILD: Fibrosis Quantification
May 400:13:26Tap to summarizeDrs. Swigris and Humphries discuss how data-driven texture analysis (DTA) on HRCT enables precise, objective quantification of fibrotic burden in ILD, overcoming the limitations of semi-quantitative visual scoring and blunt physiologic measures. They further describe a complementary AI-based classifier that predicts histologic usual interstitial pneumonia (UIP) patterns from CT, enhancing prognostication and potentially reducing the need for surgical lung biopsy.
Transcribe →HER2 in Genitourinary Cancers: Clinical Relevance and Real-World Testing Considerations
May 100:11:14Tap to summarizeDrs. Mantia and Berg discuss HER2 as a biomarker in genitourinary cancers, focusing on testing strategies, prevalence, and the clinical implications of HER2 expression and ERBB2 mutations for patient management. They also review new data from ESMO 2025, highlighting the DISTINCT-1 trial and a HER2-targeted approach for high-risk upper tract genitourinary carcinoma.
Transcribe →Could first-line ablation soon replace antiarrhythmic drugs for persistent atrial fibrillation?
Apr 3000:04:24Tap to summarizeNew cardiovascular data suggest pulsed field ablation may challenge antiarrhythmic drugs as first-line therapy for persistent atrial fibrillation, while real-world evidence positions apixaban as the preferred DOAC for younger patients with nonvalvular AF due to superior safety and effectiveness. Additional findings from the SENIOR-RITA trial indicate that routine invasive management may not benefit frail older adults with NSTEMI and could worsen outcomes in the most frail patients. Together, these studies highlight a growing shift toward more individualized cardiovascular treatment strategies.
Transcribe →Could survival in metastatic pancreatic cancer finally be improving?
Apr 2800:04:41Tap to summarizeDaraxonrasib, a first-in-class oral RAS inhibitor, nearly doubled overall survival versus chemotherapy in previously treated metastatic pancreatic cancer, representing a potentially landmark advance in a historically difficult-to-treat disease. The antibody-drug conjugate datopotamab deruxtecan significantly improved progression-free and overall survival over chemotherapy in first-line triple-negative breast cancer, particularly for patients ineligible for immunotherapy. A Cochrane review of nearly 20,000 patients found anti-amyloid Alzheimer's therapies offer minimal clinically meaningful cognitive benefit while carrying meaningful safety risks, complicating their real-world use.
Transcribe →Obstructive Hypertrophic Cardiomyopathy: The Role of Septal Reduction Therapy in the Current Era of Cardiac Myosin Inhibitors
Apr 2700:18:05Tap to summarizeDrs. Maron and Rowin review how treatment for symptomatic obstructive hypertrophic cardiomyopathy has evolved from mainly using beta blockers and invasive procedures to now including newer cardiac myosin inhibitor drugs. These newer medications more reliably reduce obstruction and improve patient symptoms and exercise capacity, but require careful safety monitoring with regular heart function checks.
Transcribe →Can shingles vaccine drastically cut risk of serious cardiac events?
Apr 2400:05:09Tap to summarizeShingles vaccination in adults with established cardiovascular disease was associated with dramatic reductions in heart attack, stroke, and mortality in a large real-world analysis, supporting its role as a cardiovascular risk-reduction tool beyond infection prevention. The VESALIUS-CV trial found evolocumab significantly reduced major cardiovascular events in high-risk diabetic patients without known ASCVD, challenging the convention of reserving PCSK9 inhibitors for secondary prevention only. AI-analyzed smartwatch data predicted heart failure hospitalizations days to weeks in advance, signaling a shift toward continuous remote monitoring in heart failure management.
Transcribe →Key Themes From the 49th Annual Macula Society Meeting
Apr 2300:09:28Tap to summarizeDrs. Yiu and Emami review key themes from the 49th Annual Macula Society Meeting, emphasizing a shift toward earlier diagnosis and intervention, longer-acting therapies, and increasing reliance on advanced imaging biomarkers and AI. They also look at new and existing data on a range of emerging treatment options for both neovascular and atrophic macular conditions.
Transcribe →